Current Status of CPX-351 Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome

Clin Lymphoma Myeloma Leuk. 2022 Aug;22(8):575-580. doi: 10.1016/j.clml.2022.02.008. Epub 2022 Feb 26.

Abstract

Acute myeloid leukemia (AML) treatment landscape had evolved over the last decades with better understanding of the disease genomics and the use of the targeted therapy, despite this treatment evolution, 7 + 3 remains the mainstay treatment for most AML cases. Many attempts had been made to improve the treatment outcome with 7 + 3 like manipulating the doses or the duration, but with no significant change in the outcome. In 2017 FDA approved CPX-351,a liposomal formulation of cytarabine and daunorubicin at a fixed 5:1 molar ratio, for the treatment of adults with newly diagnosed AML with myelodysplasia-related changes and therapy-related AML (t-AML). Since the approval, many trials were conducted or still ongoing in assessing the role of CPX-351 in treating different patient populations, AML subcategories or when combined with different agents. In this review, we will summarize the current role of CPX-351 in treating this largely heterogeneous disease.

Keywords: Acute Myeloid Leukemia; CPX -351; Induction Chemotherapy; Myelodysplastic Syndromes.

Publication types

  • Review

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Cytarabine / therapeutic use
  • Daunorubicin / therapeutic use
  • Humans
  • Leukemia, Myeloid, Acute* / drug therapy
  • Myelodysplastic Syndromes* / drug therapy

Substances

  • CPX-351
  • Cytarabine
  • Daunorubicin